pharmaphorum

DECEMBER 9, 2020

Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. of participants.

Vaccines 111

Vaccines FDA Adverse Reactions Documentation 111

European Pharmaceutical Review

DECEMBER 19, 2022

The US Food and Drug Administration (FDA) has approved Adstiladrin (nadofaragene firadenovec-vncg) as the first gene therapy for non-muscle-invasive bladder cancer (NMIBC) in adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive with carcinoma in situ (CIS) with or without papillary tumours.

FDA 87

FDA Adverse Reactions Immunization Vaccines 87

The Infectious Pharmacist

AUGUST 21, 2021

Pfizer vs. Moderna and a note on vaccine dosing and timing. You probably have read news reports about a preprint article stating that the Moderna vaccine appeared more effective than the Pfizer vaccine, at least several months after vaccination. Should I stick with the same mRNA vaccine I got for the first two doses?

Vaccines 52

Vaccines Immunization Adverse Reactions Hospitals 52

The Checkup by Singlecare

OCTOBER 6, 2023

Many drug interactions are related to additive adverse reaction profiles with concomitant medications with similar side effect profiles. Key takeaways: Methylprednisolone is an effective therapeutic agent to control immune responses and inflammation. It is best to avoid this combination of medications entirely.

Vaccines 52

Vaccines Mayo Clinic FDA Immunization 52

pharmaphorum

JULY 5, 2021

Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. While these numbers do tell us something about the relative immunity of the population writ large, they don’t tell us anything about our own, personal immune profiles. However, we’ve also found a number of outliers.

Immunization 105

Immunization Health and Personal Care Stores Vaccines Adverse Reactions 105

European Pharmaceutical Review

NOVEMBER 10, 2023

The US Food and Drug Administration (FDA) has approved Valneva SE’s IXCHIQ ® , the first chikungunya vaccine to be authorised in the world. The single-dose, live-attenuated vaccine is indicated for preventing chikungunya virus disease in individuals over 18 years old who are at increased risk of contracting the virus.

Vaccines 52

Vaccines Adverse Reactions FDA Immunization 52

pharmaphorum

SEPTEMBER 14, 2021

The UK government is due to announce a large-scale booster vaccine campaign against COVID-19 for all adults aged 50 and over later today, adding to its plan for third doses for people with weakened immune systems. A third dose of the shot was approved by the MHRA last week. Resistance to US booster plans.

Vaccines 52

Vaccines Adverse Reactions Immunization FDA 52